ДИАГНОСТИЧЕСКИЕ ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ ФЕКАЛЬНОГО КАЛЬПРОТЕКТИНА У ПАЦИЕНТОК С ВОСПАЛИТЕЛЬНЫМИ ЗАБОЛЕВАНИЯМИ КИШЕЧНИКА В ПЕРИОД БЕРЕМЕННОСТИ (обзор литературы и клинические наблюдения)

фекальный кальпротектин, воспалительные заболевания кишечника, беременность

1. Abdul Sultan, A. Adverse Pregnancy Outcomes Among Women with Inflammatory Bowel Disease: A Population-Based Study from England. / A.Abdul Sultan, J.West, L.Ban et al. // Inflamm. Bowel Dis. - 2016. - № 22. - р. 1621-1630.

2. Alibrahim, B. Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review. / B.Alibrahim, M.I.Aljasser, B.Salh // J. Gastroenterol. Hepatol. - 2015 Apr. - № 29 (3). - р. 157-63.

3. Balint, A. Pregnancy does not affect fecal calprotectin concentration in healthy women. / A.Balint, A.Berényi, K.Farkas et al. // The Turkish Journal of Gastroenterology. - 2017. - № 28 (3). -р. 171-175.

4. Bickelhaupt, S. Crohn’s disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin. / S.Bickelhaupt, S.Pazahr, N.Chuck et al. // Neurogastroenterol. Motil. - 2013 Jun. - № 25 (6). -р. 467-73.

5. Bjarnason, I. The Use of Fecal Calprotectin in Inflammatory Bowel Disease. / I.Bjarnason // Gastroenterology & hepatology. - 2017. - № 13 (1). -р. 53.

6. Boschetti, G. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. / G.Boschetti, M.Laidet, D.Moussata et al. // Am. J. Gastroenterol. - 2015. - № 110. -р. 865-872.

7. Committee Opinion. Guidelines for Diagnostic Imaging during Pregnancy. American Washington, DC, USA: College of Obstetricians and Gynecologists. - 2004.

8. Costa, F. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. / F.Costa, M.G.Mumolo, L.Ceccarelli et al. // Gut. - 2005 Mar. - № 54 (3). - р. 364-8.

9. Darr, U. Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature. / U.Darr, N.Khan // Curr. Treat. Options Gastroenterol. - 2017 Mar. - № 15 (1). - р. 116-125.

10. De Vos, M. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. / M.De Vos, E.J.Louis, J.Jahnsen et al. // Inflamm. Bowel Dis. - 2013. - № 19. - р. 2111-7.

11. De Vos, M. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. / M.De Vos, E.J.Louis, J.Jahnsen et al. // Inflamm. Bowel Dis. - 2013. - р. 19:2111-7.

12. D’Incà, R. Can calprotectin predict relapse risk in inflammatory bowel disease? / R.D’Incà, Dal E.Pont, V.Di Leo // Am. J. Gastroenterol. - 2008 Aug. -№ 103 (8). - р. 2007-14.

13. Fagerhol, M.K. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. / M.K.Fagerhol, I.Dale, T.Andersson // Bull Eur. Physiopathol. Respir. -1980. - № 16 (Suppl). - р. 273-82.

14. Garaa-Sânchez, V. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? / V.Garaa-Sânchez, E.Iglesias-Flores, R.Gonzalez et al. // J. Crohns Colitis. - 2010 Jun. -№ 4 (2). - р. 144-52.

15. Gisbert, J.P. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. / J.P.Gisbert, F.Bermejo, J.L.Perez-Calle et al. // Inflamm. Bowel Dis. - 2009 Aug. - № 15 (8). - р. 11901198.

16. Gomollôn, F. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s Disease 2016: Part 1: diagnosis and medical management. / F.Gomollôn, A.Dignass, V.Annese et al. // J. Crohns Colitis. - 2017. - № 11 (1). - р. 3-25.

17. http://ecco-jcc.oxfordjournals.org/content/ eccojc/9/2/107.full.pdf.

18. Johne, B. Functional and clinical aspects of the myelomonocyte protein calprotectin. / B.Johne, M.K.Fagerhol, T.Lyberg et al. // Mol. Pathol. - 1997. -№ 50. - р. 113-23.

19. Jones, J. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. / J.Jones, E.V.Jr.Loftus, R.Panaccione et al. // Clin. Gastroenterol. Hepatol. -2008 Nov. - № 6 (11). - р. 1218-24.

20. Julsgaard, M. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease. / M.Julsgaard, C.L.Hvas, R.B.Gearry et al. // Inflamm. Bowel Dis. - 2017 Jul. - № 23 (7). - р. 1240-1246.

21. Kallel, L. Fecal calprotectin is a predictive marker of relapse in Crohn’s disease involving the colon: a prospective study. / L.Kallel, I.Ayadi, S.Matri et al. // Eur. J. Gastroenterol. Hepatol. - 2009 Mar. -№ 22 (3). - р. 340-345.

22. Kostas, A. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. / A.Kostas, S.I.Siakavellas, C.Kosmidis et al. // World J. Gastroenterol. - 2017 Nov 7. - № 23 (41). -р. 7387-7396.

23. Langhorst, J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. / J.Langhorst, S.Elsenbruch, J.Koelzer et al. // Am. J. Gastroenterol. - 2008 Jan. - № 103 (1). -р. 162-9.

24. Lin, J.F. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. / J.F.Lin, J.M.Chen, J.H.Zuo et al. // Inflamm. Bowel Dis. - 2014 Aug. - № 20 (8). - р. 1407-15.

25. Liverani, E. How to predict clinical relapse in inflammatory bowel disease patients. / E.Liverani, E.Scaioli, R.J.Digby et al. // World Journal of Gastroenterology. - 2016. - № 22 (3). - р. 1017-1033.

26. Louis, E. Maintenance ofremission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. / E.Louis, J.Y.Mary, G.Vernier-Massouille et al. // Gastroenterology. - 2012 Jan. - № 142 (1). - р. 63-70. e5; quiz e31.

27. Magro, F. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. / E.Louis, J.Y.Mary, G.Vernier-Massouille et al. // J. Crohns Colitis. - 2017. - № 11. - р. 649-670.

28. McConnell, Ryan A. et al. Pregnancy and the Patient with Inflammatory Bowel Disease. / Ryan A.McConnell, et al. // Gastroenterology Clinics. - 2016. - № 45 (2). - р. 285-301.

29. Molander, P. Does fecal calprotectin predict short-term relapse after stopping TNFa-blocking agents in inflammatory bowel disease patients in deep remission? / P.Molander, M.Farkkila, A.Ristimaki et al. // Journal of Crohn’s & Colitis. - 2015. - № 9 (1). -р. 33-40.

30. Nguyen, G. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. / G.Nguyen, C.Seow, C.Maxwell et al. // Gastroenterology. - 2016 Mar. - № 150 (3). - p. 734757.

31. O’Toole, A. Inflammatory bowel disease increases risk of adverse pregnancy outcomes: a meta-analysis. / A.O’Toole, O.Nwanne, T.Tomlinson // Digestive diseases and sciences. - 2015. - № 60 (9). - p. 27502761.

32. Roseth, A.G. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. / A.G.Roseth, E.Aadland, J.Jahnsen et al. // Digestion. - 1997. № 58. -p. 176-80.

33. R0seth, A.G. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. / A.G.R0seth, M.K.Fagerhol, E.Aadland et al. // Scand. J. Gastroenterol. - 1992 Sep. - № 27 (9). - p. 793-8.

34. Roseth, A.G. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. / A.G.Roseth, P.N.Schmidt, M.K.Fagerhol // Scand J. Gastroenterol. - 1999. - № 34. - p. 50-4.

35. Schoepfer, A. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. / A.Schoepfer, C.Beglinger, A.Straumann et al. // Inflammatory Bowel Diseases. - 2013. - № 19 (2). - p. 332-341.

36. Schoepfer, A.M. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. / A.M.Schoepfer, C.Beglinger, A.Straumann et al. // Am. J. Gastroenterol. - 2010. - № 105 (1). p. 162-169.

37. Schweistein, H. Serum Chitinase 3-like-1 (CHI3L1) and Fecal Calprotectin Levels for Non-Invasive Disease Activity Assessment in IBD Patients During Pregnancy. / H.Schweistein, T.Adar, S.Shteingart et al. // Gastroenterology. - 2016. - № 150 (4). - S987.

38. Shitrit, A. Limitations in Using Fecal Calprotectin As a Biomarker of IBD Disease Activity During Pregnancy. / A.Shitrit, I.Miznikov, T.Adar et al. // Gastroenterology. - 2015. - № 148 (4). - S-452.

39. Sipponen, T. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. / T.Sipponen, K.L.Kolho // Scand J. Gastroenterol. -2010 Aug. - № 45 (7-8). - p. 872-7.

40. Sipponen, T. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. / T.Sipponen, E.Savilahti, K.L.Kolho et al. // Inflamm. Bowel Dis. - 2008 Jan. - № 14 (1). - p. 40-46.

41. Tibble, J.A. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. / J.A.Tibble, G.Sigthorsson, S.Bridger et al. // Gastroenterology. -2000 Jul. - № 119 (1). - p. 15-22.

42. Van Rheenen, P.F. Fecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. / P.F.Van Rheenen, E.Van de Vÿver, V.Fidler // The BMJ. - 2010. - № 341. -c3369.

43. Vermeire, S. C-reactive protein as a marker for inflammatory bowel disease. / S.Vermeire, A.G.Van, P.Rutgeerts // Inflamm. Bowel Dis. - 2004. - № 10. -p. 661-665.

44. Walkiewicz, D. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. / D.Walkiewicz, S.L.Werlin, D.Fish et al. // Inflamm. Bowel Dis. - 2008 May. - № 14 (5). -p. 669-73.

45. Walsham, N.E. Fecal calprotectin in inflammatory bowel disease. / N.E.Walsham, R.A.Sherwood // Clin. Exp. Gastroenterol. - 2016. - № 9. - p. 21-29.